• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Commentary

Marijuana Could Be the Answer to the NFL’s Pain Management Woes

By
Stephen B. Corn
Stephen B. Corn
and
Bethany Cianciolo
Bethany Cianciolo
Down Arrow Button Icon
By
Stephen B. Corn
Stephen B. Corn
and
Bethany Cianciolo
Bethany Cianciolo
Down Arrow Button Icon
August 9, 2017, 4:16 PM ET
Marijuana Cultivation Center In Nevada Ramps Up Production As State Legalizes Recreation Use Of Weed
LAS VEGAS, NV - JULY 06: David Burr demonstrates removing leaves on marijuana plants to allow more light for growth at Essence Vegas' 54,000-square-foot marijuana cultivation facility on July 6, 2017 in Las Vegas, Nevada. On July 1, Nevada joined seven other states allowing recreational marijuana use and became the first of four states that voted to legalize recreational sales in November's election to allow dispensaries to sell cannabis for recreational use to anyone over 21. Since July 1, sales of cannabis products in the state have generated more than USD 1 million in tax revenue. (Photo by Ethan Miller/Getty Images)Ethan Miller—Getty Images

Last month, it was reported that the National Football League reached out to the National Football League Players Association to scientifically explore the use of medical cannabis as a pain management tool for its players. Not only should this work help the NFL players, but their participation in these studies may likely advance pain management for the millions of people suffering with chronic pain.

As a board-certified physician specializing for over 25 years in anesthesiology, perioperative medicine, and pain medicine, and serving as an associate professor of anesthesiology at Harvard Medical School, I know how difficult it can be to treat acute and chronic pain issues. All of our sanctioned treatments have side effects, with addiction and opioid-induced respiratory arrest being among the most significant, causing much morbidity and mortality.

Chronic pain can be defined as pain lasting longer than three to six months in duration and often has a poorly defined onset. This pain is associated with subjective complaints, but objective physical signs may or may not be present as the patient adapts to the pain. Chronic pain can be devastating, affecting one’s physical and mental health. Though many treatment modalities exist, including medications (non-steroidal anti-inflammatory, opioids, and anti-depressants), peripheral nerve blocks, implantable systems (spinal cord stimulators, pain pumps), physical therapy, and acupuncture, all too often, effective pain management remains elusive.

Interestingly, each and every one of us possesses an endocannabinnoid system (ECS) that binds with cannabis. The endocannabinoid system is an internal homeostatic system that plays a critical role in the nervous system and regulates multiple physiological processes, including the modulation of pain, appetite, digestion, mood, seizure threshold, coordination, and other processes. Cannabinoid receptors exist in the brain, spinal cord, and peripheral nervous system. Further, these receptors are present in areas of the brain related to pain perception and emotion.

According to the 2017 National Academies of Science, Engineering and Medicine’s report, Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research, there is conclusive or substantial evidence that cannabis or cannabinoids are effective for the treatment of chronic pain. That report also found that there is evidence of a statistical association between cannabinoids and better outcomes (i.e., decreased mortality, decreased disability) after a traumatic brain injury.

The aforementioned biology, coupled with the scientific research evidence makes it most reasonable to explore cannabis as a means to tackle the NFL pain management challenges.

NFL players are a population of able-bodied individuals, comprising a homogenous population of males who may also have a lower prevalence of co-existing disease than other study participants from the general population. Thus, the NFL players may provide an excellent, and perhaps willing, study population for randomized controlled trials of medical cannabis.

 

Multiple outcomes could be realized from studies performed by the NFL, as they could potentially demonstrate the level of efficacy and safety of medical cannabis for the treatment of acute and chronic pain. Furthermore, the effects and safety profile of medical cannabis could be compared to that of opioid therapy, and opioid therapy in combination with medical cannabis. In addition, the level of impairment due to opioid therapy can be compared to that of medical cannabis therapy. Also, the long-term results of these NFL studies may clarify the addictive potential of medical cannabis compared to opioid therapy and may shed light on cannabis’s potential to prevent chronic traumatic encephalopathy (CTE).

Finally, from interacting with patients utilizing medical cannabis, it is evident that many just want to use enough cannabis to decrease their symptoms and improve their function so that they can perform in the home and workplace. Interestingly, an often-discussed benefit voiced by medical cannabis patients with chronic pain is their success in eliminating medication side effects by decreasing or discontinuing the use of multiple prescription pain medications by substituting with medical cannabis. Perhaps collaboration between the NFL and the National Football League Players Association can result in studies that address these issues as well, and lead to effective treatment regimes for players and chronic pain patients.

Stephen B. Corn, MD, is an associate professor of Harvard Medical School and founder of TheAnswerPage.com.

About the Authors
By Stephen B. Corn
See full bioRight Arrow Button Icon
By Bethany Cianciolo
See full bioRight Arrow Button Icon

Latest in Commentary

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Commentary

turner
CommentaryMedia
Ted Turner built the original infinite scroll. The attention economy is running on his playbook 
By Nick LichtenbergMay 12, 2026
8 hours ago
klein
CommentarySoftware
SAP CEO: the AI race is being fought in the wrong place 
By Christian KleinMay 12, 2026
15 hours ago
longevity
CommentaryLongevity
Your employees are going to live to 100. Is your benefits package ready?
By Kate Winget and Anthea Tjuanakis CoxMay 12, 2026
16 hours ago
AI strategy
CommentaryStrategy
Your company already has an AI strategy. You just didn’t choose it
By Tomas Chamorro-Premuzic, Tami Rosen and Darko LovricMay 12, 2026
17 hours ago
drew
CommentaryDefense
I helped build the Pentagon’s AI transformation. Corporate America is making every mistake we almost made
By Drew CukorMay 11, 2026
2 days ago
250
Commentary250 Years of Innovation
America’s true innovation advantage: we don’t just invent technologies — we reinvent how innovation works
By David H. HsuMay 11, 2026
2 days ago

Most Popular

Forget U.S. debt, China's total borrowing is in 'a league of its own'—much worse and deteriorating faster, analyst says
Economy
Forget U.S. debt, China's total borrowing is in 'a league of its own'—much worse and deteriorating faster, analyst says
By Jason MaMay 11, 2026
1 day ago
The Bezos family just donated $100 million to help achieve one of Mayor Zohran Mamdani’s top campaign promises
Politics
The Bezos family just donated $100 million to help achieve one of Mayor Zohran Mamdani’s top campaign promises
By Jake AngeloMay 12, 2026
7 hours ago
U.S. hotels are calling the World Cup a 'non-event' and 80% warn bookings are falling short of expectations, report finds
North America
U.S. hotels are calling the World Cup a 'non-event' and 80% warn bookings are falling short of expectations, report finds
By Sasha RogelbergMay 12, 2026
19 hours ago
Microsoft’s CFO admits she joined the tech giant without even knowing her salary—and then missed her first day of work
Success
Microsoft’s CFO admits she joined the tech giant without even knowing her salary—and then missed her first day of work
By Preston ForeMay 11, 2026
1 day ago
Nearly 50,000 Lake Tahoe residents have to find a new power source after their energy source looks to redirect lines to data centers
Travel & Leisure
Nearly 50,000 Lake Tahoe residents have to find a new power source after their energy source looks to redirect lines to data centers
By Catherina GioinoMay 12, 2026
10 hours ago
OpenAI CEO Sam Altman says Gen Z and millennials are using ChatGPT like a 'life advisor'—but college students might be one step ahead
Tech
OpenAI CEO Sam Altman says Gen Z and millennials are using ChatGPT like a 'life advisor'—but college students might be one step ahead
By Sydney LakeMay 10, 2026
3 days ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.